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development. Around 60% of the 38.000 new cancer patient 
will have a treatment in a radiotherapy department. Based 
on the figures of the Austrian Cancer registrations the cancer 
prevalence will increase dramatically in the near future 
based on the demographic trend, general increased 
expectation of life in combination with the expectations of 
higher survival rate of cancer patients. In addition, prognosis 
for cancer prevalence and cancer incidence were used to 
calculate the needed number of LIN for the year 2015, 2020 
and 2030 for Austria and Vienna.  
 
Results: There is a need for minimum 61 LIN and maximum 
86 LIN and present which implies a discrepancy of 18 LIN for 
the whole country (actual 43 LIN) for 2015. Based on the 
prognosis for cancer incidence a discrepancy of 14 LIN for 
Austria (aim 57 LIN) exists for 2015. The cancer prevalence 
prognosis shows a need for 68 LIN, which is a discrepancy of 
25 LIN for the year 2015. For the city of Vienna, the actual 
situation (12 LIN) seems appropriate, as the discrepancy for 
2015 is only 1 LIN. There is one important extra factor for 
Vienna: about 20% of all treated cancer patient come from 
Austrian neighbour districts, therefore there is a growing 
waiting list in Vienna. The entire prognosis until 2030 are 
general worse, because the results shows 2.01 mill 
inhabitants and around 8900 new cancer cases gives a need 
of 16 LIN for Vienna.  
 
Conclusion: There is a minimum discrepancy of 18 LIN for the 
whole country for 2015. One important factor for precise 
planning the resources in radiotherapy is the cancer 
prevalence. Based on the prognosis model with the cancer 
prevalence is an actual need of 25 LIN for whole Austria and 
one more in Vienna. To fulfil the constitutional law 
obligations, the government should immediately start to 
close the gap of minimum 18 LIN for the whole country. 
Austria will have in 15 years a shortage of 40 LIN (aim 73 LIN) 
and this will have a negative impact on waiting time and 
outcomes of the treatments. Never less in these calculations 
is not the included the different complexity of treatments in 
radiotherapy which need different recourses of time, staffing 
and equipment. A further project should implement these 
factors to get a much more tailored planning for the formal 
recommended radiotherapy resources in Austria. . 
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Despite the well established role of radiation in the 
treatment of solid tumor malignancies, and the rapidly 
expanding cadre of promising molecular targeting agents in 
oncology, the systematic investigation of radiation combined 
with molecular agents remains in an early dawn period. The 
increased precision of modern day radiation delivery to 
tumor targets with diminished dose exposure to normal 
tissues lends itself very favorably to combination with 
systemic therapies, particularly those tailored to specific 
molecular tumor targets. The complementary strengths of 
highly conformal radiation with molecular targeting agents 
affords a powerful opportunity to advance precision cancer 
medicine to a new level of impact for the future.  
In this presentation, we will review the rationale for 
combining radiation with molecular targeting agents and 
consider opportunities for systematic study in both the 
preclinical and clinical trials setting. Several major clinical 
trials that examine this combination will be presented and 
discussed to highlight current findings and future 
opportunities. Strategies to expand the investigation of 
radiation/molecular target combination studies will be 
previewed. In both the curative and palliative oncology 
setting, it is possible that some of the most compelling 
opportunities for improvement in cancer patient outcomes 
for the future may derive from combinations of radiation 
with molecular targeting agents.  
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Both preclinical studies and case reports have described 
synergistic interactions between local radiation (RT) and 
different types of cancer immunotherapy, demonstrating the 
potential for the combination to enhance locoregional 
efficacy and, by inducing an effective immune response 
reflect in systemic control. The latter effect, defined as 
“abscopal” is particularly relevant, since it has re-positioned 
classical radiotherapy into a treatment modality with 
systemic effects (1, 2). Our group described a role for RT in 
enhancing T cell activation and proliferation via antigen 
cross-presentation in the draining lymph node when 
combined with a diverse array of immune strategy, including 
enhancers of the priming phase (Flt-3L, GM-CSF, TLR 
agonists) or the effector phase (blocking CTLA4, PD-1, or 
TGF-beta) (3-8). Specifically, when combined with anti-CTLA-
4 we demonstrated mechanisms underlying the abscopal 
effect, including enhanced T cell homing through release of 
CXCL16 and enhancement of the immunological synapse by 
release of RAE, the ligand for NKG2D receptor (7,8). We 
further demonstrated the clonal diversity of T cell immune 
responses induced by RT alone and RT combined with 
ipilimumab in patients with metastatic non small cell lung 
cancer refractory to other treatments, and are currently 
working at detecting the specific antigens responsible for the 
immune response to the combination (unpublished data).  
However, many challenges remain to best optimize radiation 
in the context of cancer immunotherapy, both in terms of the 
choice of dose and fractionation when radiation is combined 
with immunotherapy as well as how to best block the 
immunosuppressive effects that accompany the immunogenic 
properties of radiation.  
While we have demonstrated that when combined with anti 
CTLA-4 radiation best work when hypo-fractionated, it 
remains unclear whether ablative doses are necessary to 
sustain this effect (9). Similarly, when radiotherapy is 
combined with both CTLA-4 and PD- blockade the optimal 
scheduling remain unknown. Because of the immune-privilege 
status of established tumors, it is likely for multiple 
strategies to be necessary to subvert this condition (10). 
Ideally a rseries of well orchestrated interventions should 
result in release of neo-antigens, increased permeability of 
the tumor to enhance access to antigen presenting cells and 
increased cross presentation (potentially with the addition of 
TLR agonists). The ensuing effector phase requires the 
availability of a sufficient number of T lymphocytes, a 
variable that can be assessed by measuring in the peripheral 
blood the ratio between neutrophils and lymphocytes (11). 
Blockade of immune checkpoints is also required to develop 
and sustain a robust effector response. The concurrent 
interplay of macrophages is crucial for each of the steps 
described (12). While preclinical evidence for the therapeutic 
advantage of reverting macrophage polarization from M2 to 
M1 is emerging, how to optimally combine radiotherapy 
remains elusive. Experiments of low dose radiation inducing 
M1 polarization and recovering response to immune 
checkpoint blockade are being translated to the clinic (13). 
Strategies to overcome the immunosuppressive effects of RT 
have also evolved from preclinical to clinical setting. For 
instance to overcome RT-induced activation of TGFbeta, the 
need for additional PD-1 blockade has emerged, and it 
warrants clinical testing (6). A general barrier to advance the 
field consists of the complexity of testing multiple 
immunotherapy agents, often provided by different 
pharmaceutical companies. While radiation is a standard 
modality, with well-established, organ-specific acute and 
longterm toxicities, its use in combination with each 
immunotherapy agent obeys standard clinical trials safety 
and feasibility rules, and the pace of clinical testing. To this 
